Found 4 articles for: "alopecia universalis"
Alopecia Areata in Children and the Emerging Role of JAK Inhibitors
July 2026 | Volume 25 | Issue 7 | Features | e61 | Copyright © July 2026
Post-COVID-19 Alopecia Universalis: Autoimmune Hair Loss and the Challenge of Relapse Management
September 2025 | Volume 24 | Issue 9 | Case Reports | 938 | Copyright © September 2025
Background: Alopecia universalis (AU) is the most severe form of alopecia areata (AA), characterized by complete scalp and body hair loss. While post-COVID-19 hair loss is often ...
Read MoreAlopecia Universalis: Never Give Up?
March 2025 | Volume 24 | Issue 3 | Case Reports | 316 | Copyright © March 2025
Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medicati...
Read MoreRituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid
August 2022 | Volume 21 | Issue 8 | Case Reports | 894 | Copyright © August 2022
Alopecia areata is a CD8+ T-lymphocyte driven autoimmune disorder leading to reversible hair loss. While most commonly presenting as isolated well-demarcated non-cicatricial alopecic patches on the sc...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.